Market Overview - As of May 16, 2025, the Shanghai Composite Index closed down 0.40% at 3367.46 points, while the Shenzhen Component Index fell 0.07% to 10179.60 points, and the ChiNext Index decreased by 0.19% to 2039.45 points, indicating a broad loss effect in the market [1] - The total trading volume across both markets reached 1.09 trillion yuan [1] Sector Performance - The top three sectors with gains were passenger cars (up 2.28%), auto parts (up 1.95%), and accessories (up 1.87%) [1] - The sectors with the largest declines included fisheries (down 2.27%), insurance (down 1.52%), and cosmetics (down 1.43%) [1] ETF Performance - A total of 323 non-currency ETFs rose, with an increase ratio of 28% [1] - The National Index Hong Kong Stock Connect Innovative Drug Index rose by 2.20%, with various related ETFs also showing gains, including the Hong Kong Innovative Drug ETF (up 2.62%) and the Hong Kong Stock Connect Innovative Drug ETF (up 2.35%) [1] - The latest share size of the Hong Kong Innovative Drug ETF reached 1.172 billion shares, closely tracking the National Index Hong Kong Stock Connect Innovative Drug Index [2] Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the National Index Hong Kong Stock Connect Innovative Drug Index is 24.83, which is lower than 1.22% of the time over the past three years [3] - The latest PE-TTM for the Hang Seng Innovative Drug Index is 23.51, also below 2.74% of the time over the past three years [3] Declining ETFs - A total of 730 non-currency ETFs declined, with a decrease ratio of 64% [3] - The top three ETFs with the largest declines included the Engineering Machinery ETF (down 10.00%), the Innovation 50 ETF (down 4.91%), and the New Economy ETF (down 3.99%) [5] Premium Rates - The S&P 500 Consumer Select Index showed a premium of 26.71%, while the S&P 500 Index had a premium of 13.82% [6] - The top three ETFs with the highest premium rates included the S&P Consumer ETF (26.71%), the S&P 500 ETF (13.82%), and the Saudi ETF (5.29%) [8]

作为 Orebella 英国首发的一部分，塞尔福里奇伦敦旗舰店将于 5 月 15 日至 28 日在店内中央快闪空间打 造沉浸式体验活动。该互动空间邀请宾客 "探索个人气场"，同时为其提供个性化香水推荐。消费者购 买产品即可获赠一条 Orebella 丝巾，本周末（5 月 16 日至 18 日）还可在店内为丝巾定制刺绣。与塞尔 福里奇的独家合作结束后，该品牌将于 9 月起拓展至更多销售渠道。值得一提的是，哈迪德并非首位在 塞尔福里奇大举推出个人香水品牌的名人 ——2023 年，哈里?斯泰尔斯（Harry Styles）的 Pleasing 品牌 便曾占据该百货的 Corner Shop 空间推广其香氛系列。 （原标题：超模贝拉?哈迪德的香水品牌即将登陆英国市场） Orebella 凭借以精油为基底、无酒精的 "双相" 配方，践行 "香水护肤化" 理念。这一配方意味着产品兼 具保湿护肤层与香氛层，既能滋润肌肤，又能为肌肤增添香气。专家指出，在疫情期间香水市场繁荣后 增速放缓的当下，创新香氛配方将成为成功的关键。 从戛纳红毯上亮相的贝拉?哈迪德（Bella Hadid）随后马不停蹄赶往伦敦，为其香水品牌 Orebe ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [5][20] - Gross profit rose by 53% to $4,600,000, representing 58.5% of total revenue, up from 56.2% a year ago, primarily due to increased manufacturing scale and improved yield [20][21] - Net loss for Q1 2025 was $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [21][22] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA, and recurring subscribers making up 90% of revenue [6][13] - The Amazon channel represented 20% of the business, with improvements in customer conversion and repeat purchase rates [6] - The company launched new products, including a superfood tea lineup and plans for a hydration beverage, targeting significant market segments [9][12][60] Market Data and Key Metrics Changes - The company is expanding its reach into new consumer segments and channels, including international shipping and social media platforms like TikTok [42][43] - The market for non-GMO, plant-based compounds is growing, with increasing consumer awareness of health benefits related to blood flow and longevity [8][79] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025, focusing on balancing growth with profitability [17][18] - Strategic investments will be made in expanding the direct-to-consumer portfolio, enhancing R&D processes, and building AI-powered tools for CDMO services [18] - The company is targeting a 20% adjusted EBITDA margin for its direct-to-consumer division and higher margins in the CDMO segment [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its growth strategy and deliver life-changing compounds, highlighting the synergy between the direct-to-consumer and CDMO divisions [23][70] - The company is optimistic about the increasing interest from pharmaceutical companies in its botanical synthesis technology, which offers consistent and economically viable compounds [70][71] Other Important Information - The company raised $3,900,000 in debt financing during the quarter, increasing cash and cash equivalents to $3,400,000 [22] - The company is preparing to launch the olivoboscoside cell product in 2026, targeting significant market opportunities in liver health and cholesterol management [13][79] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - Management explained that Phase two involves moving from solid media to liquid media for cell conditioning, with an expected timeline of six to nine months [27][28] Question: How long will it take to narrow down targets with Tate and Lyle? - Management indicated that significant work is underway, with a comprehensive update expected by the end of the year [30] Question: Should we expect continued gross margin expansion as revenue grows? - Management affirmed the intention to drive continued gross profit margin improvement alongside revenue growth [31][32] Question: How many products contributed to revenue in Q1, and how many are expected by year-end? - Management noted that three product lines contributed to Q1 revenue, with expectations to increase to four by Q2 and five by Q3 or Q4 [36][38] Question: Will marketing costs drop due to increased ad inventory? - Management highlighted efforts to reduce marketing costs as a percentage of revenue while exploring new channels for customer acquisition [39][44] Question: Does the second quarter guidance include contributions from the CDMO business? - Management confirmed that the guidance includes revenue recognition from existing CDMO projects and potential new catalysts [45][46] Question: How many CDMO programs can be run concurrently? - Management stated that the current capacity allows for five to seven concurrent projects in stage one [49] Question: What is the long-term opportunity for the beauty product? - Management discussed a focused strategy on high-margin categories, including health and beauty, with plans for a launch in Q1 next year [60][61]

Core Insights - United-Guardian, Inc. reported a decline in both net sales and net income for the first quarter of 2025, with net sales at $2.48 million, down 24% from $3.25 million year-over-year, and net income falling 39% to $560,895 or 12 cents per share from $925,442 or 20 cents per share [2][6] Business Segment Performance - The cosmetic ingredients segment experienced a significant decline, with sales dropping 63% year-over-year to $698,998 from $1.88 million, primarily due to a 74% reduction in orders from its largest distributor, Ashland Specialty Ingredients [3] - Pharmaceutical sales rebounded, with net sales increasing 23% to $1.17 million from $950,323 in the previous year, driven by the normalization of Renacidin supply, which saw gross sales rise 38% year-over-year to $1.23 million [4] - Medical lubricant sales grew 43% year-over-year to $613,671, benefiting from increased demand in India and China, making it the strongest performing segment [5] Management Commentary - The company's president acknowledged the challenging start to the year, attributing revenue shortfalls to the cosmetic ingredient business but highlighted the strength in medical lubricants and pharmaceuticals as positive signs [6] - Concerns were raised regarding evolving trade policies and tariffs by the U.S. government, which could introduce uncertainty for product lines tied to China markets, although the company is monitoring these risks [7] Financial Metrics - Cost of sales decreased to $1.12 million from $1.56 million year-over-year, improving as a percentage of revenues to 45% from 48% [8] - Operating expenses rose 11% to $632,735 due to higher payroll and marketing costs, while research and development expenses also increased by 11% to $114,394 [8] - Investment income and gains on marketable securities fell to $97,037 from $139,569 a year earlier, attributed to lower interest income and reduced unrealized gains [9] Future Outlook - The company expressed confidence in its long-term strategy, particularly in product development and market expansion, with plans to begin manufacturing and sales of the Natrajel product in 2025 [10] - In February 2025, United-Guardian expanded its partnership with Azelis Group NV to include South Korea and broadened coverage in the U.K. and Ireland [11]

The most recent trading session ended with e.l.f. Beauty (ELF) standing at $77.15, reflecting a -1.36% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.1%. Meanwhile, the Dow experienced a drop of 0.21%, and the technology-dominated Nasdaq saw an increase of 0.72%.Prior to today's trading, shares of the cosmetics company had gained 49.91% over the past month. This has outpaced the Consumer Staples sector's loss of 1.24% and the S&P 500's gain of 9.86% in that ...

一个小时60万件国货秒售罄，专门为老年人开了"大字慢速"直播间……昨天晚上，众多平台已经开始抢跑618，并且陆续晒出最新战报，而消费者体验发 现，今年的618更加简单直白，细分赛道服务凸显。 扬子晚报/紫牛新闻记者 徐晓风 | | 618大促满减时间 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 同期 | 展期二 屋期四 星期一 | 10.29 1 | 星期三 | | 服期五 | 服務方 | | 国用 | 5月5日 5月6日 5月9日 5月10日 | 5月11日 | 5月7日 | 5月8日 | | | | 1动 | 510周年庆(5.6日晚20点-5.12日) | | | | | | | | 玩法:分品类立减10%-15%起 | | | | | | | | 其他:首尾2场(前4小时)前N秒杀价 | | | | | | | 目開 | 5月12日 5月13日 | 5月15日 5月16日 5月17日 5月18日 | 5月14日 | | | | | 「动 | 618 HI W | | | | | | | | (5.13日晚20点-5.16日 618 ...

Company Performance - European Wax Center, Inc. (EWCZ) reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, and up from $0.13 per share a year ago, representing an earnings surprise of 340% [1] - The company posted revenues of $51.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.11%, although this is a slight decrease from year-ago revenues of $51.87 million [2] - Over the last four quarters, the company has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Outlook - European Wax Center shares have declined approximately 40.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] - The company's earnings outlook is favorable, with a current consensus EPS estimate of $0.12 on revenues of $57.77 million for the coming quarter, and $0.31 on revenues of $211.81 million for the current fiscal year [7] - The estimate revisions trend for European Wax Center is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Cosmetics industry, to which European Wax Center belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of European Wax Center may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 totaled $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [4][20] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [4][21] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [5][22] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [22] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [4][5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [4] - The entire consumer products portfolio saw strong expansion, with new product launches planned for 2025 [11][12] Market Data and Key Metrics Changes - The company is experiencing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [17][18] - There is a robust pipeline of new and potential customers for 2025, indicating strong market demand [8][19] Company Strategy and Development Direction - The company aims to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - Strategic partnerships, such as with Stata, are expected to drive growth, with plans for additional product launches in 2025 and 2026 [14][30] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product launch with AbbVie, despite delays, and sees it as a substantial opportunity [8][51] - The company does not foresee any weakness in consumer product sales and maintains guidance of $13,000,000 in revenue for 2025 [19][58] - Management is optimistic about achieving cash flow positivity in 2025, supported by ongoing innovation and growth [19][22] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [22] - The company is exploring various financing options but prefers to avoid debt until achieving EBITDA positivity [48][64] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not impact the projection of $13,000,000 [25] Question: Can you provide details on the product launching with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal decline in Silly George sales? - Management noted a slight decline but emphasized that it was the most profitable quarter despite being smaller than previous quarters [57] Question: Will transitioning manufacturing to Texas impact other business lines? - Management confirmed that there is enough capacity in the new clean room to accommodate potential shifts in manufacturing [35] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [64]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]

5月12日，2025中国国际美容化妆洗涤用品博览会（第29届CBE中国美容博览会）启幕。产业领军人物、美妆精英及国际嘉宾聚 力出席，共同启动"CBE全球美妆节"及法国主宾国仪式。时代浪潮下的全球美妆产业新机遇、新动能，在上海在CBE激荡涌 动。 第29届CBE中国美容博览会以"全球新品，首发上海"为年度主题，迎来全球40多个国家及地区的3200多家化妆品企业参展，覆 盖24个大品类、119个细分品类。10000多个美妆品牌，80000多个美妆新品爆品、科技成果同台竞技，以"首发上海∙2025CBE全 球美妆节"震撼领衔的150场创新特备活动精彩举办…… 展会第一天，来自海内外化妆品全产业链的品牌企业，全国各省市的线上线下渠道精英，欧美、亚洲的国际买家团，以及国内 外协会商会、权威主流媒体、专家等汇聚在此，展会三天预计吸引超过100个国家及地区的数十万人次的全球化妆品从业者进入 展会现场商贸洽谈、逛展打卡。 转自：潮新闻 依托科技创新与消费转型双重驱动，中国化妆品产业正展现出强劲的产业韧性与创新发展活力。 全球新品首发上海，引领美妆产业新浪潮 作为上海"首发经济"重点展会，第29届CBE中国美容博览会成为海内外 ...